

Serial No. 09/723,185

Page 2

REMARKSAmendments

Claims 52-57 are added to parallel the dependent claims 39-44, respectively, and are supported at least by such original claims.

Election of Species

The Examiner has required applicants to elect, under 35 USC §121, a single disclosed species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. The patentably distinct species of the claimed invention identified by the Examiner are SEQ ID NOs: 31-36.

Applicants hereby elect from among these species the peptide comprising SEQ ID NO:31. Claims 27-44, 46, and 52-57 are readable thereon.

Further, the Examiner states that if SEQ ID NO: 31, 32, or 33 is elected, applicants are required under 35 USC §121 to elect a single disclosed species encompassed by the claimed generic sequences that are SEQ ID NO:31-33 for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. Since SEQ ID NO:31 is elected herein, applicants further elect the species wherein Xaa(7) is Trp, Xaa(10) is Glu, Xaa(11) is Lys, Xaa(12) is Tyr, and Xaa(13) is Phe. Claims readable on this further elected species are claims 27-44, 46, and 52-57.

Following election, the claims readable on the peptide comprising SEQ ID NO:31 (and on the further elected species specifying the identity of Xaa(7), Xaa(10), Xaa(11), Xaa(12), and Xaa(13)) will be examined fully with respect to the elected species and further to the extent necessary to determine patentability. Should no prior art be found that anticipates or renders obvious the elected species, the search of the claims will be extended to the extent necessary to determine patentability of all such claims.

Attached hereto is a marked-up version of the changes made to the claims by the current amendment. The attached page is captioned "Version with markings to show changes made."

Serial No. 09/723,185

Page 3

For the Examiner's convenience, a clean copy of the currently pending claims is attached hereto.

If the Examiner has any questions, he should feel free to call the undersigned attorney at the number indicated below.

Respectfully submitted,
GENENTECH, INC.

Date: October 31, 2002

By: Janet E. Hasak
Janet E. Hasak
Reg. No. 28,616
Telephone No. (650) 225-1896



09157

PATENT TRADEMARK OFFICE

\\PFDdesktop\ : :ODMA\PCDOCS\GENENLAW\123749\1

Serial No. 09/723,185

Page 4

VERSION WITH MARKINGS TO SHOW CHANGES MADE

In the Claims:

Claims 52-57 are added as follows:

- 52. The peptide of claim 28 wherein Xaa(7) is Trp.--
- 53. The peptide of claim 28 wherein Xaa(10) is Glu.--
- 54. The peptide of claim 28 wherein Xaa(11) is Lys.--
- 55. The peptide of claim 28 wherein Xaa(12) is Tyr.--
- 56. The peptide of claim 28 wherein Xaa(13) is Phe.--
- 57. The peptide of claim 28 wherein Xaa(7) is Trp, Xaa(10) is Glu, Xaa(11) is Lys, Xaa(12) is Tyr, and Xaa(13) is Phe.--

\\PFDesktop\::ODMA\PCDOCS\GENENLAW\123749\1

Serial No. 09/723,185

Page 5

CLEAN SET OF PENDING CLAIMS

27. A constrained helical peptide comprising a sequence of nine amino acid residues having a first terminal residue and a second terminal residue, wherein said residues flank an internal sequence of seven amino acids and have side-chains covalently bonded to each other to form a locking moiety and thereby constrain the peptide.

28. The peptide of claim 27 wherein the internal sequence is Xaa(7)LeuAlaXaa(10)Xaa(11)Xaa(12)Xaa(13) (SEQ ID NO:31), wherein Xaa(7), Xaa(11), Xaa(12), and Xaa(13) are independently Nal(1), His, Phe, Trp, Tyr, Pro, Gln, or Met, and Xaa(10) is any amino acid.

29. The peptide of claim 28 wherein the first and second terminal residues are independently Asp or Glu residues.

30. The peptide of claim 29 wherein the first and second terminal residues are Glu residues.

31. A peptide comprising the following sequence:

Xaa(1-4)Xaa(5)Xaa(6-7)ProLeuGluXaa(11)LeuAlaXaa(14)Xaa(15)Xaa(16)Xaa(17)GluXaa(19) (SEQ ID NO:32), wherein Xaa(1-4) is absent or is between 1 and 4 amino acids of any kind; Xaa(5) is any amino acid, Xaa(6-7) is absent or is between 1 and 2 amino acids, Xaa(14) and Xaa(15) are independently any amino acid, Xaa(11) and Xaa(16) are independently Nal(1), His, Phe, Trp, Tyr, Pro, Gln, or Met, Xaa(17) is absent or is 1-naphthyl-Ala, His, Phe, Trp, Tyr, Pro, Gln, or Met, and Xaa(19) is absent or is Gly.

32. The peptide of claim 31 wherein Xaa(1-4) is absent and an acetyl group is attached to Xaa(5).

33. The peptide of claim 31 wherein the Glu residues in SEQ ID NO:32 are joined by forming amides with 1,5-diaminopentane.

@PFDdesktop\.:ODMA/PCDOCS/GENENLAW/123749/1

Serial No. 09/723,185

Page 6

34. The peptide of claim 31 wherein C-terminal to the C-terminal Xaa(19) is the sequence Xaa(20)ThrTyr, wherein Xaa(20) is any amino acid.
35. The peptide of claim 34 wherein Xaa(20) is Ala, Ser, Gln, Asp, Glu, or Lys.
36. The peptide of claim 31 comprising the following sequence: Xaa(5)Xaa(6-7)ProLeuGluXaa(11)LeuAlaXaa(14)Xaa(15)Xaa(16)Xaa(17)GluGly (SEQ ID NO:33), wherein Xaa(6-7) is two amino acids.
37. The peptide of claim 31 wherein Xaa(5) is Arg.
38. The peptide of claim 31 wherein Xaa(6-7) is absent or is AlaGly.
39. The peptide of claim 31 wherein Xaa(11) is Trp.
40. The peptide of claim 31 wherein Xaa(14) is Glu.
41. The peptide of claim 31 wherein Xaa(15) is Lys.
42. The peptide of claim 31 wherein Xaa(16) is Tyr.
43. The peptide of claim 31 wherein Xaa(17) is Phe.
44. The peptide of claim 31 comprising one of the following sequences: ArgAlaGlyProLeuGluTrpLeuAlaGluLysTyrGluGly (SEQ ID NO:34); ArgProLeuGluTrpLeuAlaGluLysTyrPheGlu (SEQ ID NO:35); or ArgAlaGlyProLeuGluTrpLeuAlaGluLysTyrPheGlu (SEQ ID NO:36).
46. The peptide of claim 31 that contains 10-60 amino acids.
52. The peptide of claim 28 wherein Xaa(7) is Trp.

\\PFDesktop\1:ODMA\PCDOCS\GENENLAW\123749\1

Serial No. 09/723,185

Page 7

53. The peptide of claim 28 wherein Xaa₍₁₀₎ is Glu.
54. The peptide of claim 28 wherein Xaa₍₁₁₎ is Lys.
55. The peptide of claim 28 wherein Xaa₍₁₂₎ is Tyr.
56. The peptide of claim 28 wherein Xaa₍₁₃₎ is Phe.
57. The peptide of claim 28 wherein Xaa₍₇₎ is Trp, Xaa₍₁₀₎ is Glu, Xaa₍₁₁₎ is Lys, Xaa₍₁₂₎ is Tyr, and Xaa₍₁₃₎ is Phe.

@PFDesktop\.:ODMA/PCDOCS/GENENLAW/123749/1